Median Technologies offers AI‑powered imaging platforms that convert raw medical images into actionable clinical and trial data. Its eyonis® suite, including the FDA‑cleared eyonis® LCS for lung cancer screening, provides high‑sensitivity detection and diagnostic insights, while the iCRO and iSee® tools automate image management, quality control, and biomarker extraction for oncology drug development and patient care.
Funding
$22.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oncology drug development and clinical care suffer from limited access to quantitative, AI-driven insights from medical imaging, leading to slower trial timelines, variable diagnostic accuracy, and missed opportunities for early cancer detection.
Solution
Median Technologies provides AI-powered imaging platforms and centralized imaging services that transform raw medical images into actionable clinical and trial data. Their eyonis® suite, including the FDA‑cleared eyonis® LCS for lung cancer screening, uses proprietary computer vision and signal‑processing algorithms to detect and characterize lesions with high sensitivity and specificity. For biopharma sponsors, Median offers the iCRO image management system and iSee® software to automate image quality control, extract drug efficacy biomarkers, and streamline central reads across global trial sites. The platform integrates with existing PACS and clinical workflows, delivering standardized reports and predictive biomarkers that support patient selection, companion diagnostics, and precision diagnosis. By combining AI analytics with a worldwide network of 7,000+ sites, Median accelerates oncology trial execution and enhances early, non‑invasive cancer diagnosis.
Target Audience
Primary customers are pharmaceutical companies and CROs conducting oncology clinical trials, as well as radiology and oncology clinicians seeking AI‑enhanced diagnostic tools for early cancer detection.
Features
- AI/ML‑driven computer‑aided detection and diagnosis (CADe/CADx) for lung cancer screening with 93.3% sensitivity and 92.4% specificity
- Proprietary iCRO image management platform for centralized QC, storage, and analytics across 2,500+ clinical sites
- iSee® clinical trial imaging software that automates workflow integration, image reads, and real‑time metrics
- Predictive imaging biomarker discovery and patient selection tools for oncology drug development
- Seamless PACS integration and support for FDA‑cleared Software as a Medical Device (SaMD) deployments
- Global operational support with dedicated project managers and scientific directors for phase I‑III oncology studies